

CSD/BSE&NSE/2023-2024  
November 14, 2023

**To**  
**The Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400001**  
**Scrip Code: 543064**

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400051**  
**Scrip Symbol: SUVENPHAR**

Dear Sir/Madam,

**Sub: Intimation under Regulation 31A (8)(c) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)**

.....

We wish to inform you that Suven Pharmaceuticals Limited (“**Company**”) has received request from: (i) Jasti Property and Equity Holdings Private Limited (in its capacity as sole trustee of Jasti Family Trust); (ii) Mr. Venkateswarlu Jasti; (iii) Ms. Sudharani Jasti; (iv) Ms. Kalyani Jasti; (v) Ms. Sirisha Jasti; and (vi) Ms. Madhavi Jasti respectively ((i) – (vi) collectively referred to as the “**Outgoing Promoters**”), for the reclassification from the Promoter and Promoter Group Category to public in accordance with Regulation 31A of the SEBI Listing Regulations (more particularly Regulation 31A(10) of the SEBI Listing Regulations given that the intent to reclassify of the Outgoing Promoters has been disclosed, *inter-alia*, in the letter of offer dated 10 October 2023 (in relation to the open offer of Suven Pharmaceuticals Limited)) which was taken on record by the board of directors of the Company at its meeting.

In this regard please note that the Company has submitted today (i.e., November 14, 2023) the application for reclassification to the BSE Limited and the National Stock Exchange of India Limited in accordance with Regulation 31A of the SEBI Listing Regulations (more particularly Regulation 31A(10) of the SEBI Listing Regulations).

We request you to kindly take the aforementioned on record as required under the SEBI Listing Regulations (more particularly Regulation 31A(8)(c) of the SEBI Listing Regulations).

## **Suven Pharmaceuticals Limited**

The Company shall update the status of the reclassification application upon the receipt of necessary approvals, in accordance with the SEBI Listing Regulations (more particularly Regulation 31A(8)(d) of the SEBI Listing Regulations).

This is for your information and record.

Thanking you,  
Yours faithfully,

**For Suven Pharmaceuticals Limited**

**K. Hanumantha Rao**  
Company Secretary

## **Suven Pharmaceuticals Limited**

Registered Office: # 8-2-334 | SDE Serene Chambers | 3rd Floor | Road No.5  
Avenue 7 | Banjara Hills | Hyderabad - 500034 | Telangana | India | CIN: L24299TG2018PLC128171  
Tel: 91 40 2354 9414 /1142 /3311 | Fax: 91 40 2354 1152 | Email: info@suvenpharm.com | www.suvenpharm.com